National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Sublingual Immunotherapy (Grazax®)

A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax®) for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.

Pharmaoeconomic Evaluation

Commenced Completed Outcome
September 2007 Reimbursement not recommended

The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.

 Sublingual Immotherapy (Grazax) summary